Carisma Therapeutics Q3 2024 Earnings Report

Carisma Therapeutics EPS Results

• Actual EPS: -$0.31
• Consensus EPS: -$0.31
• Beat/Miss: Met Expectations
• One Year Ago EPS: N/A

Carisma Therapeutics Revenue Results

• Actual Revenue: $3.39 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Carisma Therapeutics Announcement Details

• Quarter: Q3 2024
• Date: 11/7/2024
• Time: N/A

Carisma Therapeutics (NASDAQ:CARM), a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.